These findings revealed that the mRNA expression levels of RAB32 demonstrated a gradual increase in WHO II, WHO III, and WHO IV gliomas (Figure 2B), and were positively correlated with the glioma grading as confirmed by high-throughput microarray analysis, which was consistent with data obtained from other sources (Figure 2E). This evidence concerns the gene RAB32 and central nervous system cancer.